KPC Pharmaceuticals,Inc. (SHA:600422)

China · Delayed Price · Currency is CNY

8.11

+0.11 (1.38%)

Sep 30, 2026, 3:00 PM CST

Market Cap	6.14B -42.2%
Revenue (ttm)	4.87B -38.8%
Net Income	-212.36M
EPS	-0.28
Shares Out	756.98M
PE Ratio	n/a
Forward PE	38.02
Dividend	0.18 (2.22%)
Ex-Dividend Date	Jul 30, 2026

Volume	4,325,588
Open	8.00
Previous Close	8.00
Day's Range	7.97 - 8.15
52-Week Range	7.45 - 14.46
Beta	-0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2026

About KPC Pharmaceuticals,Inc.

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People’s Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections, and other products, as well as engages in the wholesale and retail of medicines and equipment. ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1951

Employees 5,072

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600422

Full Company Profile

Financial Performance

In 2025, KPC Pharmaceuticals,Inc.'s revenue was 6.58 billion, a decrease of -21.74% compared to the previous year's 8.40 billion. Earnings were 349.94 million, a decrease of -46.00%.

Financial Statements